Design of more potent quinazoline derivatives as EGFRWT inhibitors for the treatment of NSCLC: a computational approach
Open Access
- 12 July 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Future Journal of Pharmaceutical Sciences
- Vol. 7 (1), 1-11
- https://doi.org/10.1186/s43094-021-00279-3
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- The inhibitory activity of aldose reductase of flavonoid compounds: Combining DFT and QSAR calculationsJournal of Taibah University for Science, 2016
- Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutantBioorganic & Medicinal Chemistry, 2016
- Comparison of single-agent chemotherapy and targeted therapy to first-line treatment in patients aged 80 years and older with advanced non-small-cell lung cancerOncoTargets and Therapy, 2015
- Targeted therapy for non-small cell lung cancer: current standards and the promise of the future2015
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRThe New England Journal of Medicine, 2010
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790MNature, 2009
- Targeting protein kinases in central nervous system disordersNature Reviews Drug Discovery, 2009
- ChemDraw Ultra 10.0 CambridgeSoft, 100 CambridgePark Drive, Cambridge, MA 02140. www.cambridgesoft.com. Commercial Price: $1910 for download, $2150 for CD-ROM; Academic Price: $710 for download, $800 for CD-ROM.Journal of the American Chemical Society, 2006
- EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2005
- The discovery of receptor tyrosine kinases: targets for cancer therapyNature Reviews Cancer, 2004